Showing results (1321-1330 of 1,459) with videos related to
Sort By:
Pageof 146
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.Biorxiv : the Preprint Server for Biology|February 20, 2025
Multiplex, multimodal mapping of variant effects in secreted proteinsNicholas A Popp, Rachel L Powell, Melinda K Wheelock, et al.Nature Ecology & Evolution|March 27, 2025
Pervasive gene flow despite strong and varied reproductive barriers in swordtailsStepfanie M Aguillon, Sophia K Haase Cox, Quinn K Langdon, et al.Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.Nature Structural & Molecular Biology|June 13, 2025
Multiplex and multimodal mapping of variant effects in secreted proteins via MultiSTEPNicholas A Popp, Rachel L Powell, Melinda K Wheelock, et al.European Journal of Cancer Care|September 6, 2008
A message of hope: creation of the Faces of Lung Cancer project for increasing awareness of clinical trialsG P Quinn, B A Bell-Ellison, M Y Bell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.Leukemia|March 23, 2018
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studiesAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.Pageof 146